openPR Logo
Press release

Japan Generics Drug Market Japan Generics Sales Report 2020

07-11-2017 12:24 PM CET | Health & Medicine

Press release from: Kuick Resarch

Japan Generics Drug Market Japan Generics Sales Report 2020

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Report Table of Contents

1. Introduction to Japan Generic Drug Market
1.1 Reasons for Growth of Japan Generic Market
1.2 Some Misconceptions Related to Generic Drugs in Japan

2. Attractiveness of Japan Generic Market
2.1 Overview of Japan Pharmaceutical Market
2.2 Features of Japan Generic Drugs Market
2.3 Generic Drug Firms in Japan
2.4 Generic Drugs Import in Japan
2.5 Economic Views about Generic Drugs

3. Scenario of Generic Drugs in Japan
3.1 Scenario for Generic Drug Discount Price in Japan
3.2 Different Categories of Pharmaceutical Patent in Japan
3.3 Promotion of Generic Drugs in Japan

4. Super Generics in Japan
4.1 Introduction to Super Generics
4.2 Advantages of Super Generics
4.3 Disadvantages of Super Generics

5. Different Parameters for Generic & Branded Drugs in Japan
5.1 Patent Protection in Japan
5.2 Effect on Japan Healthcare Spending
5.3 Japan Pharmacological Parameters for Generic Drugs
5.4 Difference in Regulatory Requirements
5.5 Utilization of Branded & Generic Drugs in Japan Market

6. Generic Active Pharmaceutical Ingredients in Japan
6.1 Generic Active Pharmaceutical Ingredient Registration
6.2 Regulation for Foreign Companies in Japan
6.3 Manufacturing Capabilities for Generic API

7. Health in Japan & Utilization of Generic Drugs
7.1 Cancer Incidences in Japan
7.2 Increasing Diabetes Incidences in Japan
7.3 Increasing Cerebrovascular Incidences in Japan
7.4 Cardiovascular Diseases Incidences in Japan
7.5 Disease Caused by Pollution in Japan

8. Healthcare System & Generic Drugs in Japan
8.1 Universal Healthcare Coverage
8.2 Price Rise Control
8.3 Quality Control of Generic Drugs
8.4 Access to Generic Market
8.5 Patents Related Issues to Generic Drugs in Japan
8.6 Factors Restricting Uptake of Generic Drugs in Japan

9. Comparison of Generic Drugs in US & Japan
9.1 Regulatory Framework for Generic Drugs
9.2 Market Penetration of Generic Drugs
9.3 Prices of Generic Drugs
9.4 Perception towards Generic Drugs

10. Japan Generic Drugs Market Analysis

11. Japan Generic Market Favorable Factors
11.1 Ageing Population
11.2 Generic Drugs Regulations
11.3 High Technological Capabilities
11.4 Increasing Disease Incidences

12. Japan Generics Market Commercialization Challenges
12.1 Japan Regulatory Environment
12.2 Attitude towards Generic Drugs
12.3 Lower uptake of Generic Drugs
12.4 Conflicting Patent Laws

13. Japan Generic Drugs Market Future Prospects

14. Competitive Landscape
14.1 Actavis
14.2 Eisai
14.3 Fuji Pharma
14.4 GlaxoSmithKline
14.5 Hospira
14.6 Meiji Seika Pharma
14.7 Nichi-Iko Pharmaceutical
14.8 Nipro Pharma
14.9 Pfizer
14.10 Sawai Pharmaceuticals
14.11 Takeda Pharmaceutical
14.12 Towa Pharmaceutical

Download Report: https://www.kuickresearch.com/report-Japan-Generics-Drug-Market-Outlook-2020.php

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Japan Generics Drug Market Japan Generics Sales Report 2020 here

News-ID: 619028 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Generic

Generic Injectables Market growth is attributed to the increasing demand for Onc …
According to Precision Business Insights (PBI), the latest report, the generic injectables market will be worth USD 22.0 billion in 2022, growing at an 11.0% CAGR from 2022 to 2028. The global generic injectables market is segmented into the following types: Product Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Blood Factors, Immunoglobulins, Peptide Antibiotics, Vaccines, and Others), Indication (Diabetes, Cancer, Cardiovascular Diseases, Musculoskeletal, CNS, Infections, and Others), Distribution Channel (Hospital
A Demand On Generic Drugs Market And The Need To Push The Market Of Generic Drug …
Global Generic Drugs Market A generic drug is pharmaceutical drug, which is bio-equivalent to a branded drug in all forms such as route of administration, strength, dosage, quality, intended use and performance. Generic drugs are usually approved after patent expiration of patent drugs. Generic drugs are safe, effective and FDA approved. The global market is filled with 44% of generic drugs. The global generic drugs market is driven by the rise of
Generic Wellness Offers Special Discount on Generic Xenical for Fat Reduction !
This week a special offer is introduced by Generic Wellness for weight loss treatment with an oral drug called generic Xenical. The drug is an excellent weight loss treatment for all men and women above the age of 12. People who have taken this drug for weight loss have actually experienced the benefits like reduction of unwanted fat in the body. This is possible with generic Xenical because of the
Generic Drugs Market Trends 2025
Generic drugs market growth is buoyed by increasing number of expiries of patented drugs each year. According to the IMS data small-molecule products worth US$ 121 Bn are expected to lose patents in developed markets, such as U.S ad Europe between 2014 and 2018. The IMS also forecasts that biologic products valued at US$ 48 Bn are expected to lose patent protection over the next three years i.e from 2017
Generic Drugs Market - Global Competitive Analysis
Generic drugs market growth is buoyed by increasing number of expiries of patented drugs each year. According to the IMS data small-molecule products worth US$ 121 Bn are expected to lose patents in developed markets, such as U.S ad Europe between 2014 and 2018. The IMS also forecasts that biologic products valued at US$ 48 Bn are expected to lose patent protection over the next three years i.e from 2017
Generic Drug Market: Global Generic Drug Share to Reach USD 380.60 Billion by 20 …
Zion Market Research has published a new report titled “Generic Drug Market by Brand (Pure Generic and Branded Generic) for Central Nervous System (CNS), Cardiovascular, Dermatology, Oncology, Respiratory and Others Therapeutic Applications - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021”. According to the report, the global generic drug market accounted for around USD 200.20 billion in 2015 and is expected to reach approximately USD 380.60 billion by